Seres Therapeutics Inc.

09/12/2024 | Press release | Distributed by Public on 09/12/2024 05:16

Seres Therapeutics Reports SER 155 Phase 1b Placebo Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.